Physician profile
Nayan Patel
NPI 1518099654
$6,351.70
in general payments reported to CMS, 2019-2025
37 companies · $2,226 in 2025
The $2,226 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $545 · 2021: $11.85 · 2022: $1,160 · 2023: $327 · 2024: $1,376 · 2025: $2,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,786 · Long Term Medical Supply Or Device Loan: $127 · Education: $16.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,786.24 |
| Long Term Medical Supply Or Device Loan | $127.22 |
| Education | $16.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,160.00 | 2022 | |
| Gilead Sciences, INC. | $958.39 | 2019-2025 | |
| Genzyme Corporation | $512.17 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $503.53 | 2023-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $283.52 | 2019-2025 | Trulance, Xifaxan |
| Abbvie INC. | $258.87 | 2019-2025 | |
| Janssen Biotech, INC. | $246.05 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $241.26 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $235.71 | 2024-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $230.05 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $222.86 | 2024-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $218.29 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $209.91 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $156.61 | 2024-2025 | Zenpep, Vowst |
| Pentax of America, INC. | $127.22 | 2023 | Plasmatyphoon |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $112.04 | 2019-2025 | Ocaliva |
| Novo Nordisk INC | $111.26 | 2025 | |
| Celgene Corporation | $72.16 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $51.18 | 2025 | Rezdiffra |
| Celltrion USA INC. | $46.00 | 2024-2025 | Vegzelma |
| Shionogi INC | $44.54 | 2019-2020 | |
| Braintree Laboratories, INC. | $36.09 | 2024 | Sutab, Suflave |
| Organon LLC | $32.06 | 2024 | |
| Orphalan INC | $28.49 | 2025 | Cuvrior |
| Merck Sharp & Dohme LLC | $28.26 | 2024 | Dificid |
| Bayer Healthcare Pharmaceuticals INC. | $26.71 | 2019 | |
| Mirum Pharmaceuticals, INC. | $26.31 | 2025 | Livmarli |
| Eisai INC. | $23.93 | 2019 | |
| Pfizer INC. | $23.03 | 2025 | |
| Nestle Healthcare Nutrition INC. | $22.54 | 2023 | |
| Grifols USA, LLC | $20.66 | 2020 | |
| Intra-Sana Laboratories | $20.30 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boston Scientific Corporation | $17.92 | 2019 | |
| Capsovision, INC. | $15.00 | 2025 | Capsocam Plus |
| Integra Lifesciences Corporation | $14.99 | 2024 | Cusa Clarity, Codman Certas, Codman Hakim |
| Allergan, INC. | $13.79 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,285.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nayan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.